An Exploratory Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy

Trial Profile

An Exploratory Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2005

At a glance

  • Drugs Romidepsin (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top